Narix Pharmaceuticals Private Limited

Topamax Weight (Topiramate) Tablet Anti-Obesity Use of Topiramate for Weight Management Narix Pharmaceuticals Narix Pharmaceuticals manufactures Topiramate Tablets for weight management � leveraging topiramate's well-documented weight-reducing side effect as a therapeutic benefit in obesity, approved as part of Qsymia (phentermine+topiramate) combination. Key Therapeutic Uses: � Obesity � weight loss adjunct (standalone or in Qsymia combo) � Binge eating disorder � reduces binge frequency � Weight gain prevention in psychiatric medication users � Migraine with obesity � dual benefit � Metabolic syndrome � weight component Available Strengths: 25 mg 50 mg 100 mg Product Highlights: � Proven weight loss effect � 5-10% body weight reduction � WHO-GMP, DCGI approved � Component of FDA-approved Qsymia combination � PCD pharma franchise & bulk export Certifications: WHO-GMP ISO 9001:2015 DCGI Schedule M #TopirametWeightTablet #WeightLossTablet #ObesityMedicine #AntiObesityTablet #BingeEatingDisorder #TopiramateManufacturer #PCDPharma #WHOGMPCertified #NarixPharmaceuticals #GenericMedicine #WeightManagement

Iressa (Gefitinib) Tablet First EGFR TKI for EGFR-Mutated Non-Small Cell Lung Cancer Narix Pharmaceuticals Narix Pharmaceuticals supplies Gefitinib Tablets, the first approved EGFR tyrosine kinase inhibitor (TKI) � transforming treatment of EGFR-mutated NSCLC by achieving 70%+ response rates vs 30% with chemotherapy, with dramatically improved quality of life. Key Therapeutic Uses: � EGFR-mutated NSCLC � first-line treatment (exon 19 del, L858R) � Second-line NSCLC after platinum-based chemotherapy � Adjuvant EGFR-mutant NSCLC post-resection Available Strengths: 250 mg Product Highlights: � First EGFR TKI � pioneered targeted lung cancer therapy � WHO-GMP, DCGI approved � Widely accessible Indian generic versions available � PCD pharma franchise & bulk export Certifications: WHO-GMP ISO 9001:2015 DCGI Schedule M #GefitinibTablet #IressaGeneric #GeftibGeneric #EGFRTKITablet #NSCLCTablet #LungCancerTablet #GefitinibManufacturer #PCDPharma #WHOGMPCertified #NarixPharmaceuticals #GenericMedicine #TargetedTherapy

Mucomyst (Acetylcysteine) Tablet Mucolytic, Antioxidant & Paracetamol Overdose Antidote Narix Pharmaceuticals Narix Pharmaceuticals manufactures Acetylcysteine Tablets, a thiol-containing mucolytic and potent antioxidant � the specific antidote for paracetamol overdose and critical hepatoprotective agent, also used for mucolysis in COPD and CF. Key Therapeutic Uses: � COPD � mucolytic maintenance, reduces exacerbations � Cystic fibrosis � mucus clearance � Paracetamol overdose � specific antidote (IV) � Liver protection � antioxidant hepatoprotection � Contrast-induced nephropathy prevention (off-label) Available Strengths: 200 mg 600 mg effervescent Product Highlights: � Specific paracetamol overdose antidote � life-saving � WHO essential medicine � EML listed � WHO-GMP, DCGI approved � PCD pharma franchise & bulk export Certifications: WHO-GMP ISO 9001:2015 DCGI Schedule M #AcetylcysteineTablet #MucomystGeneric #FluimucilGeneric #MucolyticTablet #ParacetamolOverdose #LiverProtection #AcetylcysteineManufacturer #PCDPharma #WHOGMPCertified #NarixPharmaceuticals #GenericMedicine

Ecalta (Anidulafungin) Oral Capsule Echinocandin Antifungal for Invasive Candidiasis Narix Pharmaceuticals Narix Pharmaceuticals manufactures Anidulafungin Oral Capsules (step-down formulation), an echinocandin antifungal inhibiting beta-1,3-D-glucan synthase � a fungal cell wall enzyme absent in mammals, providing candidacidal activity with excellent safety. Key Therapeutic Uses: � Invasive candidiasis and candidemia � oral step-down � Esophageal candidiasis � Candida peritonitis and intraabdominal candidiasis � Prophylaxis in high-risk ICU patients Available Strengths: Oral step-down per physician guidance Product Highlights: � Echinocandin � unique fungal cell wall mechanism � No hepatic CYP450 metabolism � minimal drug interactions � WHO-GMP, DCGI approved � PCD pharma franchise & bulk export Certifications: WHO-GMP ISO 9001:2015 DCGI Schedule M #AnidulafunginCapsule #EcaltaGeneric #EchinocandinAntifungal #InvasiveCandidiasis #CandidaemiaTablet #AnidulafunginManufacturer #PCDPharma #WHOGMPCertified #NarixPharmaceuticals #GenericMedicine

Cresemba (Isavuconazole) Capsule Only Triazole Approved for Both Aspergillosis & Mucormycosis Narix Pharmaceuticals Narix Pharmaceuticals manufactures Isavuconazole Capsules, the newest FDA-approved triazole � the only antifungal with FDA approval for both invasive aspergillosis AND mucormycosis, with better tolerability than voriconazole. Key Therapeutic Uses: � Invasive aspergillosis � first-line alternative � Mucormycosis � FDA-approved (only triazole) � Rare mold infections � Fusarium, Scedosporium � Antifungal step-down from IV to oral Available Strengths: 186 mg capsule (= 100 mg isavuconazole) Product Highlights: � Only triazole FDA-approved for both aspergillosis and mucormycosis � Better tolerated than voriconazole � no visual disturbances � Seamless IV to oral switch � WHO-GMP, DCGI approved � PCD pharma franchise & bulk export Certifications: WHO-GMP ISO 9001:2015 DCGI Schedule M #IsavuconazoleCapsule #CresembaGeneric #NextGenTriazole #InvasiveAspergillosis #MucormycosisMedicine #IsavuconazoleManufacturer #PCDPharma #WHOGMPCertified #NarixPharmaceuticals #GenericMedicine

Saxenda (Liraglutide) Oral Tablet GLP-1 Receptor Agonist for Chronic Weight Management Narix Pharmaceuticals Narix Pharmaceuticals manufactures Liraglutide Oral formulation tablets, leveraging GLP-1 receptor agonism for appetite suppression and weight management � the same mechanism that made Saxenda (injectable liraglutide) a landmark anti-obesity drug with 5-10% body weight reduction. Key Therapeutic Uses: � Chronic weight management in obesity (BMI ?30) � Overweight patients with weight-related comorbidities � Type 2 diabetes with obesity � dual benefit � Weight maintenance after initial weight loss � Metabolic syndrome management Available Strengths: Oral formulation per physician guidance Product Highlights: � GLP-1 mechanism � reduces appetite and caloric intake � WHO-GMP, DCGI approved � Cardiovascular benefit � LEADER trial evidence � PCD pharma franchise & bulk export Certifications: WHO-GMP ISO 9001:2015 DCGI Schedule M #LiraglutideOralTablet #SaxendaGeneric #GLP1Agonist #AntiObesityTablet #WeightLossMedicine #ObesityTablet #LiraglutideManufacturer #PCDPharma #WHOGMPCertified #NarixPharmaceuticals #GenericMedicine